Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Conditions
Interventions
ADCT-502
Locations
5
United States
Stanford Cancer Center
Palo Alto, California, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Memorial Hospital
New York, New York, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States
Medical Oncology Clinic - Institut Jules Bordet
Brussels, Belgium
Start Date
May 18, 2017
Primary Completion Date
April 5, 2018
Completion Date
April 5, 2018
Last Updated
February 1, 2021
NCT05468034
NCT04541381
NCT05671510
NCT03137095
NCT04852887
NCT07547774
Lead Sponsor
ADC Therapeutics S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions